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Targeting survivin as a potential new treatment
for chondrosarcoma of bone
Y de Jong1, JG van Oosterwijk1, AB Kruisselbrink1, IH Briaire-de Bruijn1, G Agrogiannis1,2, Z Baranski3, AHG Cleven1,
A-M Cleton-Jansen1, B van de Water3, EHJ Danen3 and JVMG Bovée1
Chondrosarcomas are malignant cartilage-forming bone tumors, which are intrinsically resistant to chemo- and radiotherapy,
leaving surgical removal as the only curative treatment option. Therefore, our aim was to identify genes involved in
chondrosarcoma cell survival that could serve as a target for therapy. siRNA screening for 51 apoptosis-related genes in JJ012
chondrosarcoma cells identiﬁed BIRC5, encoding survivin, as essential for chondrosarcoma survival. Using immunohistochemistry,
nuclear as well as cytoplasmic survivin expression was analyzed in 207 chondrosarcomas of different subtypes. Nuclear survivin has
been implicated in cell-cycle regulation while cytoplasmic localization is important for its anti-apoptotic function. RT–PCR was
performed to determine expression of the most common survivin isoforms. Sensitivity to YM155, a survivin inhibitor currently in
phase I/II clinical trial for other tumors, was examined in 10 chondrosarcoma cell lines using viability assay, apoptosis assay and
cell-cycle analysis. Survivin expression was found in all chondrosarcoma patient samples. Higher expression of nuclear and
cytoplasmic survivin was observed with increasing histological grade in central chondrosarcomas. Inhibition of survivin using
YM155 showed that especially TP53 mutant cell lines were sensitive, but no caspase 3/7 or PARP cleavage was observed. Rather,
YM155 treatment resulted in a block in S phase in two out of three chondrosarcoma cell lines, indicating that survivin is more
involved in cell-cycle regulation than in apoptosis. Thus, survivin is important for chondrosarcoma survival and chondrosarcoma
patients might beneﬁt from survivin inhibition using YM155, for which TP53 mutational status can serve as a predictive biomarker.
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INTRODUCTION
Chondrosarcoma is a malignant cartilage-forming tumor account-
ing for 20% of all malignant bone tumors.1 Chondrosarcomas
represent a heterogeneous group as different histological
subtypes are recognized, including conventional, dedifferentiated,
mesenchymal, clear cell and periosteal chondrosarcoma. The
conventional subtype is most frequent (85%)1 and can be further
categorized into central chondrosarcoma (485%) (in medullar
cavity) and peripheral chondrosarcoma (at the bone surface).2
Histologically, atypical cartilaginous tumors (ACT) (previously
referred to as grade I chondrosarcomas) show low cellularity
and are locally aggressive, but do not metastasize. High-grade
chondrosarcomas comprise grade II and III chondrosarcomas and
show higher cellularity, mitoses and less cartilaginous matrix.
Histological grading represents the most important prognostic
factor; patients with atypical cartilaginous tumors show a 10-year
overall survival rate of 83%, patients with grade II tumors show
64% survival and patients with grade III chondrosarcomas show
29% 10-year survival rate.1,2 Dedifferentiated chondrosarcomas
comprise 10% of all chondrosarcomas and are characterized by a
high-grade dedifferentiated component juxtaposed to a low-
grade cartilaginous component. Patients with dedifferentiated
chondrosarcoma show a 5-year overall survival between 7 and
24%.3 Mesenchymal chondrosarcoma is a rare (o3%) high-grade
chondrosarcoma subtype with reported 10-year survival rates
between 27 and 67%.4,5 Histologically, it consists of differentiated
cartilage mixed with undifferentiated small round cells.6
Chondrosarcomas are intrinsically resistant to conventional
chemo- and radiotherapy, and therefore surgical removal of the
tumor is the only curative treatment option. Several studies
have been performed investigating possible new therapeutic
targets for the treatment of chondrosarcoma. This has led to
several discoveries including mTOR,7,8 Src9,10 and Bcl-2 family
members11,12 as possible targets but still no targeted therapies are
available for chondrosarcoma patients. Therefore, there is still an
urgent need for novel therapeutic targets that can be easily and
rapidly applied in the treatment of patients with high-grade
metastatic or inoperable chondrosarcoma.
To identify new cancer drug targets, high-throughput RNA
interference (RNAi) screens are widely used and have led to several
important ﬁndings regarding new cancer gene discoveries.13 Loss
of function RNAi screens have led to the identiﬁcation of
important oncogenes in several different cancer types, such as
the identiﬁcation of Brd4 as a therapeutic target in acute myeloid
leukemia14 and MED12 as a determinant of drug response to
tyrosine kinase inhibitors in non-small cell lung cancer.15 As RNAi is
a powerful tool to discover survival-related genes in a speciﬁc
manner, we performed an siRNA screen targeting 51 genes involved
in apoptosis regulation to identify genes involved in survival of
chondrosarcoma cells that could serve as a potential target for
therapy for patients with inoperable or metastatic chondrosarcoma.
To validate our results, we used a unique panel of chondrosarcoma
cell lines including conventional, dedifferentiated and mesenchymal
subtypes, reﬂecting the heterogeneity of chondrosarcoma of bone.
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RESULTS
BIRC5 is an essential survival gene in chondrosarcoma cells
An siRNA screen targeting 51 apoptosis-related genes revealed
that HRK (Harakiri, BCL2 Interacting Protein), BIRC5 (Baculoviral IAP
Repeat Containing 5), BCL2L1 (B-cell/Lymphoma 2 like 1), BCL-10
(B-cell/Lymphoma 10) and CRADD (CASP2 And RIPK1 Domain
Containing Adaptor With Death Domain) were essential genes in
the JJ012 chondrosarcoma cell line (Figure 1a). Across the primary
screen, transfection with control siRNAs led to a slight (~13%)
reduction in viability compared with mock whereas positive
control siKIF11 caused a very strong (490%) loss of viability
indicating successful gene silencing and a good experimental
window (Figure 1b). The average Z’factor was 0.61, which
indicates a qualitatively good screen. Deconvolution was
performed for selected hits, and BCL2L1, BIRC5, CRADD and HRK
were conﬁrmed (Supplementary Figure 1). Identiﬁcation of HRK
and CRADD is surprising as these encode pro-apoptotic proteins.
A role for BCL2L1 in chondrosarcoma has been previously
described by us.11 Here, we focused on BIRC5 (Figure 1c),
which encodes the survivin protein, an anti-apoptotic protein
overexpressed in human cancers.16
Survivin is highly expressed in chondrosarcoma tumor tissue and
cell lines
Survivin protein expression and its subcellular localization were
determined in 207 chondrosarcomas of different subtypes.
Nuclear expression, suggesting a role for survivin in cell-cycle
progression, was found in 90/98 conventional chondrosarcomas.
Cytoplasmic expression, reﬂecting its function in apoptosis
regulation, was found in 97/98 conventional chondrosarcomas.
Expression levels were variable. Both nuclear and cytoplasmic
survivin expression increased with increasing histological grade in
central chondrosarcoma (Figures 2a and b). Cytoplasmic survivin
expression was signiﬁcantly higher in grade II (P⩽ 0.001) and III
(P⩽ 0.01) central chondrosarcomas compared with ACTs. Also,
higher expression of nuclear survivin was observed in grade III
chondrosarcomas compared with ACTs (P⩽ 0.05). No correlation
was found with IDH1 or -2 mutation status (not shown). Moreover,
survivin was also highly expressed in dedifferentiated, clear cell
and mesenchymal chondrosarcoma. Survivin expression was
signiﬁcantly higher in nuclei compared with the cytoplasm in
the well-differentiated part of dedifferentiated chondrosarcoma
(P⩽ 0.001) (Figures 2c and d). Also in clear cell chondrosarcoma,
nuclear expression was signiﬁcantly higher (P⩽ 0.001) compared
with cytoplasmic expression (Figure 2c).
Nuclear survivin expression is associated with p53 overexpression
in high-grade conventional chondrosarcoma
As p53 is a known effector of survivin expression,17 we
investigated a possible correlation between p53 overexpression
(indicative of a mutated TP53 gene) and survivin expression using
the conventional chondrosarcoma tissue micro array (TMA). p53
overexpression was observed in 0/50 grade I, 20/41 grade II and
9/17 grade III conventional chondrosarcomas (Figures 3a and b). In
high-grade chondrosarcomas (grade II and III) with overexpression
Figure 1. Screening for apoptotic regulators identiﬁes BIRC5 as an important survival gene in chondrosarcoma cell line JJ012. (a) Occupied
area of cells present in the well as a percentage to control siRNA of 51 apoptosis-related genes. Mean values and range of duplicates are
shown. (b) Raw data measured as Hoechst area of controls used in the siRNA screen. Dots indicate individual measurements and mean values
are shown for each control. siCTR indicates control siRNA of either GFP or GAPDH. (c) Area of cells as a percentage to control siRNA of selected
hits. BIRC5 shows 4/4 siRNAs that mimic the smart pool. Data represent means of duplicate values with range. Black bars represent the smart
pool and gray bars represent individual siRNAs.
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of p53, the expression of nuclear survivin was higher as compared
with high-grade chondrosarcomas without overexpression of p53
(P⩽ 0.01 for grade 3) (Figure 3c). No difference between peripheral
and central conventional chondrosarcoma was observed (data not
shown).
Survivin isoforms are highly expressed in high-grade
chondrosarcoma
The three most common survivin isoforms, wild type (wt) survivin,
survivin 2b and survivin Δex3, were all expressed signiﬁcantly
higher in high-grade chondrosarcomas (grade II and III)
compared with low-grade chondrosarcomas (P⩽ 0.001 for wt
survivin, P⩽ 0.01 for survivin 2b and P⩽ 0.05 for survivin Δex3)
(Figures 4a–c). No signiﬁcant difference in survivin expression
was observed between IDH wt and IDH1 or -2 mutant
chondrosarcomas (not shown). Furthermore, a correlation was
found between all different survivin isoforms (Supplementary
Figure 2).
Chondrosarcoma cell lines highly express survivin, predominantly
in the nucleus
We conﬁrmed that all cell lines showed high expression of
survivin protein, predominantly in the nucleus (Figure 5a and
Supplementary Figure 3). All survivin isoforms were highly
expressed compared with normal articular cartilage (Figure 5b).
Using the Ion AmpliSeqCancer Hotspot Panel v2, the IDH1 or -2
mutation status was conﬁrmed (Supplementary Table 1). For TP53,
the use of this highly sensitive targeted next-generation
sequencing technique provided novel insights for CH2879
and L2975, which were previously reported to be wild
type (Supplementary Table 1).18–20 In CH2879, a subclonal
pathogenic mutation was found with a frequency of 17%, which
corresponded to the mosaic staining pattern of nuclear p53
observed in the cell pellet and primary tumor (Supplementary
Figure 4). The mRNA expression levels of survivin were not
correlated with TP53 or IDH1 or -2 mutational status (not shown).
Chondrosarcoma cell lines are sensitive to survivin inhibition
using YM155
YM155 is a compound currently in phase I/II clinical trial that
represses survivin promoter activity.21 We ﬁrst assessed the effect
of YM155 on survivin RNA downregulation (Figure 5b). JJ012,
SW1353 and L835 cell lines showed clear downregulation of all
three survivin isoforms after YM155 treatment. NDCS1 only
showed downregulation of survivin Δex3 after YM155 treatment,
and L2975 only showed downregulation of survivin 2b.
Figure 2. Survivin is highly expressed in high-grade chondrosarcoma. (a) Immunohistochemical analysis of survivin in conventional
chondrosarcoma showing higher cytoplasmic expression in grade II and III central chondrosarcoma compared with ACTs. Also higher
expression of nuclear survivin is observed in grade III chondrosarcomas compared with ACTs. Each dot represents one patient, and mean
value with standard deviation is shown for each group. (b) High cytoplasmic survivin expression in a grade III chondrosarcoma.
(c) Immunohistochemical analysis of nuclear and cytoplasmic survivin in dedifferentiated, clear cell and mesenchymal chondrosarcoma.
Nuclear survivin is highly expressed in nuclei of the well-differentiated part of dedifferentiated chondrosarcoma and clear cell
chondrosarcoma compared with the cytoplasmic part. Each dot represents one patient, and mean value with standard deviation is shown
for each group. (d) High nuclear survivin expression in dedifferentiated chondrosarcoma (dedifferentiated part).
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Chondrosarcoma cell lines were highly sensitive to YM155
showing IC50 values below 5 nM in four out of ten chondrosarcoma
cell lines (SW1353, OUMS27, NDCS1, L2975) (Figures 5c and d).
JJ012 showed an IC50 of 8.2 nM and CH3573 showed an IC50 of
12.32 nM. The least responsive cell lines were L835, CH2879,
L3252B and MCS170. Interestingly, three of these are TP53 wt
(P= 0.033) (Figure 5e and Supplementary Table 1). There was no
relation between YM155 sensitivity and histological subtype or
IDH1 or -2 mutation status. Combination treatment of YM155 with
doxorubicin and cisplatin did not show a synergistic effect in JJ012
and SW1353 cell lines (Supplementary Figure 5).
The survivin inhibitor YM155 does not induce caspase 3/7 or
PARP-dependent apoptosis in chondrosarcoma cells
No activation of apoptosis was found in chondrosarcoma cell lines
after treatment with IC75 concentrations of YM155. Caspase 3/7
activation was not observed after 24 or 48 h of treatment
(Figure 6a and data not shown). Furthermore, treatment with
pan-caspase inhibitor z-VAD could not restore the reduction in
viability observed after treatment with YM155 (Figure 6b). PARP
expression but not cleaved PARP was observed in CH2879 and
NDCS1 cell lines (Figure 6c), however not in SW1353 and only low
expression was observed in JJ012.
Figure 3. P53 is highly expressed in high-grade conventional chondrosarcoma and correlated with nuclear survivin in grade III
chondrosarcoma. (a) Immunohistochemical analysis of p53 expression in conventional chondrosarcoma. Grade II and III chondrosarcomas
show signiﬁcantly higher expression compared with grade I chondrosarcoma (Po0.0001). Each dot represents one patient, and mean value
with standard deviation is shown for each group. (b) High nuclear p53 expression in a high-grade chondrosarcoma. (c) Low nuclear p53
expression in a high-grade chondrosarcoma. (d) Correlation between nuclear survivin and p53 overexpression in conventional
chondrosarcoma. P53 is considered as overexpressed when it reached a sum score of 4 (indicated by +). Grade I chondrosarcomas did
not show p53 overexpression. In grade II chondrosarcoma, higher nuclear survivin was seen in p53 overexpressing chondrosarcomas, as well
as in grade III chondrosarcoma (Po0.01) compared with low p53 expressing tumors. Each dot represents one patient, and mean value with
standard deviation is shown for each group.
Figure 4. Survivin wt, 2b and Δex3 isoforms are highly correlated and show higher expression in high-grade chondrosarcoma as determined
by Q-PCR analysis. (a–c) Survivin isoforms wt (a), 2b (b) and Δex3 (c) are highly expressed in high-grade (grade II and III) chondrosarcoma
compared with low-grade (ACT) chondrosarcoma. No expression is found in cartilage while variable expression is seen in growth plate tissue.
Each dot represents one measurement, and mean values are shown for each group.
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YM155 deregulates the cell cycle in a subset of chondrosarcoma
cell lines
Because no activation of apoptosis was found in chondrosarcoma
cell lines treated with YM155, we evaluated its effect on the cell
cycle (Figure 6d). A large increase in S phase and a reduction in G1
were observed in JJ012 cells after 48 h of treatment. CH2879
showed only minor effects in cell-cycle distribution after YM155
treatment and NDCS1 cells did not show any change in cell-cycle
distribution after treatment with YM155. Knock down of BIRC5 in
JJ012 cells also resulted in a deregulation of the cell cycle
(Supplementary Figure 6).
DISCUSSION
For patients with inoperable or metastatic chondrosarcoma,
no treatment options are available resulting in a 10-year survival
rate below 30%.1 By using a focused RNAi screen targeting core
apoptosis machinery components, we identiﬁed BIRC5 as an
important player in chondrosarcoma survival and we here show
that survivin inhibition using YM155 could be a promising novel
treatment strategy for this malignant tumor.
BIRC5 encodes the survivin protein which is part of the inhibitor
of apoptosis family, and is involved in a large variety of cellular
processes in the nucleus as well as in the cytoplasm. Nuclear
survivin functions in the cell cycle as an essential mitotic regulator
being a member of the chromosomal passenger complex.
On the other hand, cytoplasmic survivin is predominantly
involved in preventing apoptosis.16 Overexpression is found in
many tumor types including osteosarcomas22 and soft tissue
sarcomas.23 Moreover, survivin upregulation was previously
shown in small series of conventional chondrosarcomas.24–26 We
here demonstrate high survivin expression in conventional as well
as rare chondrosarcoma subtypes in a large panel of 4200
chondrosarcomas. Expression was found both in the nucleus and
in the cytoplasm in high-grade conventional chondrosarcomas,
suggesting a function both in the cell cycle and as an anti-
apoptotic protein. In contrast, in dedifferentiated and clear cell
chondrosarcomas, survivin was predominantly expressed in
the nucleus, suggesting a more prominent role for survivin in
cell-cycle regulation.
We also show a positive correlation between nuclear
survivin and p53 overexpression in conventional chondrosarcoma.
Figure 5. Chondrosarcoma cell lines are sensitive to YM155, which is p53 dependent. (a) JJ012 cell line showing strong survivin expression.
(b) Normalized RNA expression of three survivin isoforms in eight chondrosarcoma cell lines. JJ012, SW1353 and L835 show a clear reduction
in survivin expression after YM155 treatment. Growth plate and cartilage are taken as a control. Bars represent mean with standard deviation.
(c, d) Dose response curves for YM155 (72 h) in conventional subtypes (c) and rare chondrosarcoma subtypes (d). Error bars are shown for
three experiments performed in triplicate. (e) IC50s determined for TP53 wt and mutant cell lines showing a signiﬁcantly increased sensitivity
of TP53 mutant cell lines toward YM155. Bars represent mean values of three experiments performed in triplicate.
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High p53 expression is known to correlate with increasing
histological grade in chondrosarcoma27 and is suggestive for
mutated TP53.28 Wild-type p53 was shown to be able to repress
survivin expression,17 which may explain the higher survivin
expression in chondrosarcomas with high, probably mutated,
p53 expression.
Survivin isoforms are differentially expressed in different types
of cancer correlating with survival, depending on the isoform.
In chondrosarcoma, we found increased expression of all three
isoforms with increasing histological grade. SurvivinΔΕx3 has been
most extensively studied and has been associated with a worse
prognosis in breast, colon and cervical cancer.29 In soft tissue
sarcomas, all survivin transcripts were strongly overexpressed
compared with non-malignant control tissue and elevated
expression of survivinΔΕx3 was correlated with a worse
survival.30 Survivin was expressed in normal growth plate tissue,
suggesting a role for survivin in endochondral ossiﬁcation. This is
in concordance with the role for survivin described in tissue
development and its downregulation with differentiation.31 No
survivin expression was detected in normal articular cartilage,
which is in concordance with the low expression levels observed
in other normal adult tissues,31 rendering survivin a very attractive
therapeutic target.32
We here show for the ﬁrst time that survivin inhibition using
YM155 could be a promising novel treatment strategy for
chondrosarcoma as YM155 was highly potent in reducing cell
viability. YM155 is already in phase I and II clinical trials, so could
be readily applicable in clinical trials for chondrosarcoma patients.
It is an indirect inhibitor of survivin that blocks the survivin
promoter region by binding and disrupting the RNA binding
protein ILF3/NF110, thereby preventing survivin transcription.33
Another proposed mechanism is disruption of binding of zinc
Figure 6. YM155 does not cause caspase 3/7 and PARP-dependent apoptosis, but cell-cycle deregulation in chondrosarcoma cell lines.
(a, b) Caspase 3/7 activity (a) and viability (b) after 24 h as percentage to untreated control measured in nine chondrosarcoma cell lines by
caspase-glo assay and presto blue viability assay. No caspase 3/7 activity is seen after YM155 treatment in all cell lines. Pan Caspase inhibitor
z-vad was not able to rescue the YM155-dependent reduction in viability. MCS170 cells treated with doxorubicin and ABT-737 were used as a
positive control. Error bars are shown for two independent experiments performed in duplicate. (c) Western blot analysis for PARP and cleaved
PARP expression in four chondrosarcoma cell lines. No differences are seen between treated (+) and untreated (–) samples. Alpha tubulin was
used as a loading control. Jurkat cell lysates treated with 25 μM etoposide obtained from Cell Signaling were used as a positive control.
(d) FACS analysis of three chondrosarcoma cell lines treated with YM155 for 48 h. JJ012 and CH2879 show a reduction in G1 and an increase in
S phase after treatment with YM155. NDCS1 is not showing a difference in cell-cycle distribution.
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transcription factor SP1 to the survivin promoter by YM155.34
Interestingly, TP53 mutant cell lines were more sensitive to YM155
as compared with TP53 wt cell lines, suggesting that the TP53
mutation status could be a predictive biomarker. This was also
found in other cancer cell lines.35 In TP53 wt cell lines, mechanisms
other than survivin may dominate tumor cell proliferation and
survival.
YM155 does not induce apoptosis in the chondrosarcoma cell
lines, as shown by the absence of caspase 3 and 7 activity and of
PARP cleavage. In previous studies, YM155 was shown to induce
apoptosis in leukemia, prostate cancer and breast cancer.36
However, in merkel cell carcinoma, YM155 did not induce
apoptosis but inhibited DNA synthesis.37 Survivin is predominantly
expressed during G2/M phase of the cell cycle,38 and its inhibition
is expected to cause a G2/M arrest. G2/M phase cell-cycle arrest
has been described by Lechler et al.25 in two chondrosarcoma cell
lines after siRNA knock down of survivin; however, Yang et al.26
showed a decrease in S phase after knock down of survivin in the
same cells.26 We found an increase in S phase after treatment with
YM155 in two of our chondrosarcoma cell lines and an increase
in G2/M phase in JJ012 cells after BIRC5 knock down. This
inconsistency can be caused by several issues including different
conﬂuency of the cells, different methods to inhibit survivin and
different incubation times before the measurement.
Consistent with our ﬁndings, Brun et al.39 also observed a block
in S phase after treatment with YM155 in sonic hedgehog-driven
medulloblastoma. We did not observe a difference in cell-cycle
distribution in all cell lines, which shows that chondrosarcoma cell
lines show a heterogeneous response toward YM155 treatment.
In our hands, combination treatment of YM155 with
doxorubicin or cisplatin did not result in synergistic inhibition of
viability in two chondrosarcoma cell lines, suggesting that survivin
is not involved in chondrosarcoma chemo resistance. However,
Lechler et al.25 previously reported on a synergistic induction of
apoptosis after combining survivin siRNA with doxorubicin
treatment in two chondrosarcoma cell lines. This can possibly be
attributed to the different cell lines and the different mechanism
of inhibition used to target survivin.
Phase I and II clinical trials have already been conducted for
YM155 as a single agent as well as in combination with
chemotherapy for a few tumor types.36 Phase I studies show that
YM155 is well tolerated; however, larger phase II studies in diffuse
large B-cell lymphoma, non-small cell lung cancer, melanoma and
prostate cancer do not show very promising results regarding
anti-tumor activity.36 This does not necessarily mean that this will
also be the case for chondrosarcoma, especially since we show
here that in chondrosarcoma instead of the induction of
apoptosis, YM155 causes a block in the cell cycle, and that
patients can be preselected based on TP53 mutation status. New
survivin inhibitors, for example, antisense oligonucleotides and
survivin-based vaccines, are in development and some already
reached clinical trials.40
In conclusion, we show that survivin is essential for
chondrosarcoma cell survival and is highly expressed in high-grade
chondrosarcomas and absent in normal cartilage. Chondrosarcoma
cell lines are highly sensitive for treatment with YM155, especially
if TP53 is mutant, indicating that survivin could be a possible new
therapeutic target for patients with chondrosarcoma.
MATERIALS AND METHODS
Cell culture
Central conventional chondrosarcoma cell lines SW1353 (ATCC), JJ012,41
CH2879,18 OUMS27,42 CH357343 and L835, and dedifferentiated
chondrosarcoma cell lines L3252B, L297520 and NDCS144 were cultured
in RPMI-1640 (Gibco, Invitrogen Life Technologies, Scotland, UK)
supplemented with 1% penicillin/streptomycin (100 U/ml) and 10 or 20%
Fetal Calf Serum (Gibco, Invitrogen Life Technologies). Mesenchymal
chondrosarcoma cell line MCS170 was cultured in IMDM medium
(Gibco, Invitrogen Life Technologies) supplemented with 1% penicillin/
streptomycin (100 U/ml) and 15% Fetal Calf Serum (Supplementary
Table 1). All cell lines were cultured at a temperature of 37 °C in a
humidiﬁed incubator (5% CO2). Identity of cell lines was conﬁrmed using
the Cell ID GenePrint 10 system (Promega Benelux BV, Leiden, The
Netherlands) before and after completion of the experiments. Mycoplasma
tests were performed on a regular basis.
Mutation analysis
Mutations in TP53, IDH1 and IDH2 were conﬁrmed with Ion
AmpliSeqCancer Hotspot Panel v2 (Life Technologies, Thermo Fisher
Scientiﬁc, Waltham, MA, USA, catalog number 4475346) according to the
manufacturer’s instructions. Sanger sequencing was performed when
validation was necessary (Supplementary Table 1). TP53 mutations
identiﬁed were analyzed using prediction software Align GVGD and
Sorting Intolerant From Tolerant (SIFT). Also entries in the Catalogue of
Somatic Mutations in Cancer (COSMIC) database were analyzed.
Compounds
The survivin inhibitor YM155 (Catalog No. S1130, Selleckchem, Munich,
Germany) and BH3 mimetic ABT-737 (Catalog No. S1002, Selleckchem) were
dissolved in DMSO according to the manufacturer’s instructions. Doxorubicin
and cisplatin were obtained from the in-house hospital pharmacy in a 0.9%
NaCl solution. Z-vad-FMK (550377, BD Biosciences San Jose , CA, USA) was
used as a general caspase inhibitor and dissolved in DMSO.
siRNA screen
To identify critical genes for chondrosarcoma cell survival, a focused
targeted siRNA screen was performed on the JJ012 central
chondrosarcoma cell line targeting 51 apoptosis-related genes
(Dharmacon, GE Life Sciences, Landsmeer, the Netherlands)
(Supplementary Table 2). In the primary screen, reverse transfection of
SMARTpools of four different siRNAs in a ﬁnal concentration of 50 nM for
each gene was performed using DharmaFECT 3 transfection reagent
(Thermo Fisher Scientiﬁc Inc., T-2003). Deconvolution conﬁrmation screens
were performed where each of four individual siRNAs was transfected
separately. A gene was considered as a hit when three out of four
individual siRNAs mimicked the SMARTpool. GFP or GAPDH siRNAs were
used as negative and KIF11 siRNAs were used as positive controls.
Mock (no siRNA) transfection served as an additional control. The
transfection was performed in duplo in u-clear 96-well black clear bottom
plates (Corning BV Life Sciences, Amsterdam, The Netherlands) using
7000 cells/well. After 1 day, the medium was replaced. After 5 days, cells
were ﬁxed with formalin and stained with Hoechst. Nuclei present in each
well were imaged using a BD-pathway microscope (BD Biosciences).
Quantiﬁcation was performed by determining the total Hoechst area using
the Image Pro analyzer software (Media Cybernetics, Rockville, MD, USA)
and normalizing toward negative controls. Z’factor analysis was performed
as a quality control using the mean of siGFP and siGAPDH as a negative and
siKIF11 as a positive control.
Immunohistochemistry
Survivin and p53 expression was evaluated in human primary chondrosarcoma
tumor tissue using previously constructed tissue microarrays containing 137
conventional chondrosarcomas (92 central of which 42 grade I, 36 grade II, 14
grade III and 45 peripheral including 31 grade I, 11 grade II, 3 grade III)10 and 10
chondrosarcoma cell lines. Additionally, survivin expression was evaluated in
20 clear cell, 21 mesenchymal and 25 dedifferentiated chondrosarcomas.12
For dedifferentiated chondrosarcoma, the well-differentiated and the dediffer-
entiated component were scored separately. To visualize survivin, the 71G4B7
antibody (Rabbit mAb #2808, Cell Signaling Technology, Leiden, The Nether-
lands) was diluted 1:100, and placenta was used as a positive control. p53
expression was determined using an antibody from DAKO (M700101, Heverlee,
Belgium) in a 1:800 dilution with tonsil as positive control tissue.
Immunohistochemistry was performed according to standard laboratory
methods, using citrate (pH 6) as antigen retrieval method, as previously
described.45 Survivin is known to be expressed in the nucleus as well as in
cytoplasm displaying different functions and prognostic signiﬁcance.46 There-
fore, nuclear and cytoplasmic expression was scored separately for each core
by two independent observers (JVMGB and GA) using a scoring system
assessing staining intensity (0=no, 1=weak, 2=moderate, 3= strong) and
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percentage of staining (0=no, 1=1–24%, 2=25–49%, 3=50–74%,
4=75–100%).12 p53 expression was considered as high when added scores
were ⩾4, as previously described.27 Cores that were lost from the TMA section
were excluded from the analysis (n=39 for conventional chondrosarcomas,
n=3 for clear cell chondrosarcoma, n=7 for mesenchymal chondrosarcoma
and n=4 for dedifferentiated chondrosarcoma). Slides were scanned using a
Philips intellisite pathology scanner (Philips Healthcare, Brussel, Belgium), and
pictures were taken using a Philips IMS viewer (Philips Healthcare).
RNA isolation and quantitative real-time PCR
RNA was isolated from fresh frozen tissue of 34 conventional
chondrosarcoma primary tumor tissues (Supplementary Table 3) and 6
cartilage control tissues, that is, three growth plate, and three articular
cartilage tissues. RNA was also isolated from untreated and YM155 treated
cell lines. For isolation, TRIzol (Invitrogen, Carlsbad, CA, USA) was used
followed by RNA clean up using the RNeasy mini kit (Qiagen, Venlo, The
Netherlands) according to the manufacturer's instructions. All patient
samples were handled according to the ethical guidelines described in
‘Code for Proper Secondary Use of Human Tissue in The Netherlands’ of
the Dutch Federation of Medical Scientiﬁc Societies. Q-PCR was performed
for wild type (wt) survivin, survivin 2b and survivin Δex3 with primers
described previously.47 Expression was normalized toward housekeeping
genes PPIA, CPSF6 and GPR108, as previously described.48
Viability assay
Chondrosarcoma cell lines were plated in 96-well plates so as to achieve
50–70% conﬂuency the following day. Dose response curves were performed
using concentrations from 0.01 till 1000 nM. Concentrations used for
combination studies were 10 and 50 nM doxorubicin, 250 and 1000 nM
cisplatin and 1 and 5 nM YM155, and combinations of drugs were added at the
same moment. After 72 h of incubation, a presto blue assay (Life Technologies,
Scotland, UK) was performed according to the manufacturer’s instructions.
Fluorescence was measured reading the plate at 590 nm on a ﬂuorometer
(Victor3V, 1420 multilabel counter, Perkin-Elmer, Groningen, the Netherlands).
Experiments were performed at least three times in triplicate.
Apoptosis
To measure apoptosis, the caspase-glo 3/7 assay (Promega, Madison, WI,
USA) was used according to the manufacturer’s instructions. In brief, cells
were plated into white walled 96-well plates (Corning BV Life Sciences,
Amsterdam, The Netherlands) and incubated with IC75 concentrations of
YM155 (determined using 72 h viability assays). After 24 h, the substrate
was added in a 1:1 dilution and incubated for 30 min at room temperature.
As a positive control, MCS170 cells treated with ABT-737 and doxorubicin
were used. Luminescence was measured using a luminometer (Victor3V,
1420 multilabel counter, Perkin-Elmer). Experiments were performed at
least two times in duplicate.
Western blotting
Western blotting for PARP (Cell Signaling Technology) was performed on
lysates obtained using hot-SDS buffer (1% SDS, 10 mM Tris/EDTA with
complete inhibitor and phosSTOP) as previously described.9 For PARP and
cleaved PARP detection, Jurkat cell lysates treated with 25 μM etoposide
obtained from Cell Signaling Technology (#2043) were used as a positive
control. Of each sample, 20 μg protein was loaded on the gel. As a loading
control, α-tubulin (clone DM1A, Sigma-Aldrich Chemie BV, Zwijndrecht,
The Netherlands) expression was determined. Proteins were blotted onto a
PVDF membrane and detected using enhanced chemo luminescence
(Pierce ECL Western Blotting Substrate Fisher Scientiﬁc, Landsmeer, the
Netherlands) followed by exposure of 1 min and development of the ﬁlm
(ECL hyperﬁlm, Amersham, GE Healthcare, Eindhoven, the Netherlands).
Cell-cycle analysis
Cells were plated in T25 ﬂasks in amounts ensuring 70% conﬂuency when
harvested. For knock down experiments, cells were seeded in 6-well plates.
After 48 h of treatment with YM155 IC50 concentrations or BIRC5 or GAPDH
siRNA, cells were prepared for cell-cycle analysis using methanol and
propidium iodide staining as previously described.49 Cell-cycle data
analysis was performed using WinList 7.1 (Verity Software House, Topsham,
ME, USA). Experiments were performed at least two times in duplicate.
Statistical analysis
Mann–Whitney testing was applied using the Prism 6 GraphPad software
(La Jolla, CA, USA) to assess signiﬁcant differences between survivin
expression levels. Bonferroni correction was used to correct for multiple
testing. Dose response curves and IC50 values were determined using the
Prism 6 GraphPad software.
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